Health Care Technology
GLP-1S Associated With Reduced Asthma Exacerbation In Patients Without Diabetes
Share
GLP-1 initiation is associated with a 14.6% reduced risk of asthma exacerbation for overweight patients,
12.2% for obese patients and 13.3% for morbidly obese patients
MILWAUKEE, Feb. 15, 2026 /PRNewswire/ -- Glucagon-like peptide-1 receptor agonists (GLP-1) is linked to a significant reduction in asthma exacerbations for overweight, obese and morbidly obese patients without diabetes, according to new research being presented at the 2026 AAAAI Annual Meeting.
"Asthma exacerbations can be disruptive for patients, especially those living with obesity, who often have fewer effective treatment options. Our findings suggest that GLP-1 receptor agonists may be associated with fewer asthma exacerbations in non-diabetic patients, pointing to a promising new direction that could ultimately improve day-to-day asthma control and quality of life," said primary author Ruchi Patel, MD.
Researchers used data from the global collaborative network in TriNetX to conduct this cohort study of overweight (BMI 25.00 - 29.99 kg/m2), obese (BMI 30.00 - 40.00 kg/m2) and morbidly obese (BMI at least 40.00 kg/m2) non-diabetic patients with asthma. The study compared exacerbation rates over a three-year period between participants initiating a GLP-1 receptor agonist and those without GLP-1 exposure.
After propensity matching within the study, the overweight cohorts included 710 patients, the obese cohorts included 1,515 patients and the morbidly obese cohorts included 1,249 patients. In the overweight group, the GLP-1 initiation was associated with a reduced risk of asthma exacerbation with a risk ratio of 0.748 and a risk difference of 14.6%. In the obese group, GLP-1 use was also associated with a reduced risk of exacerbation with a risk ratio of 0.790 and a risk difference of 12.2%. Similarly, in the morbidly obese group, GLP-1 initiation was associated with a reduced risk of exacerbation with a risk ratio of 0.780 and a risk difference of 13.3%.
By exploring the effects of GLP-1s in patients without diabetes, this research provides a unique insight into a potential benefit of GLP-1 therapy and the effects of weight loss on asthma exacerbations.
Visit aaaai.org to learn more about asthma. Research presented at the 2026 AAAAI Annual Meeting, February 27 – March 2 in Philadelphia, PA, is published in an online supplement to The Journal of Allergy and Clinical Immunology (JACI).
The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists and other professionals with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI is the go-to resource for patients living with allergies, asthma and immune deficiency disorders.
View original content to download multimedia:https://www.prnewswire.com/news-releases/glp-1s-associated-with-reduced-asthma-exacerbation-in-patients-without-diabetes-302687344.html
SOURCE American Academy of Allergy, Asthma & Immunology (AAAAI)
Frequently Asked Questions
What did the new research discover about GLP-1 receptor agonists?
New research indicates that GLP-1 receptor agonists are associated with a significant reduction in asthma exacerbations for overweight, obese, and morbidly obese patients who do not have diabetes.
What was the magnitude of risk reduction observed?
GLP-1 initiation was associated with a 14.6% reduced risk for overweight patients, 12.2% for obese patients, and 13.3% for morbidly obese patients.
Who conducted this study and where was it presented?
The study was conducted by researchers using TriNetX data, with primary author Ruchi Patel, MD. It was presented at the 2026 AAAAI Annual Meeting.
First published on Mon, Feb 16, 2026
Liked what you read? That’s only the tip of the tech iceberg!
Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!
Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.
Dive into TechDogs' treasure trove today and Know Your World of technology like never before!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
Mesirow Again Ranked Among Top Chicago Area Wealth Management Firms
Vaital Named By Inc. To 2026 List Of Fastest-Growing Private Companies On The West Coast
ACES India Enables Seamless 4G & 5G Connectivity At Noida International Airport Ahead Of Launch
DESTINUS Named To Fast Company's Annual List Of The World's Most Innovative Companies Of 2026
Exscape Group Announces New Partnership With Buckeye Landscape Service
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion